Peter A. McCue, MD

Contact Dr. McCue

132 S. 10th Street
Main Building, Suite 285
Philadelphia, PA 19107

(215) 955-5588

Most Recent Peer-reviewed Publications

  1. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
  2. Targeting VPAC1 Receptors for Imaging Glioblastoma
  3. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance
  4. FOXD3 Regulates VISTA Expression in Melanoma
  5. Small extracellular vesicles modulated by αVβ3 integrin induce neuroendocrine differentiation in recipient cancer cells
  6. The αvβ6 integrin in cancer cell-derived small extracellular vesicles enhances angiogenesis
  7. Prostate Contrast Enhanced Transrectal Ultrasound Evaluation of the Prostate With Whole-Mount Prostatectomy Correlation
  8. Pleiotropic impact of DNA-PK in cancer and implications for therapeutic strategies
  9. Tumor-Derived Extracellular Vesicles Require β1 Integrins to Promote Anchorage-Independent Growth
  10. PARP-1 regulates DNA repair factor availability
  11. ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma
  12. Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response
  13. Transplant glomerulopathy
  14. Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer
  15. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
  16. Detailed Analysis of Insulin Absorption Variability and the Tissue Response to Continuous Subcutaneous Insulin Infusion Catheter Implantation in Swine
  17. VAPC-1 Targeted 64Cu-TP3805 kit preparation and its evaluation
  18. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: The largest single-institution experience to date
  19. Common Variable Immunodeficiency Disease and Rectal Squamous Cell Carcinoma: a Case Report of a Rare Syndromic Tumor Type
  20. Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors